Inhibition of the PI3K/AKT/mTOR pathway in solid tumors

PM LoRusso - Journal of clinical oncology, 2016 - ascopubs.org
The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular
processes and is frequently altered in cancer, contributing to tumor growth and survival …

PTEN/PTENP1:'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy

N Haddadi, Y Lin, G Travis, AM Simpson, NT Nassif… - Molecular cancer, 2018 - Springer
Regulation of the PI-3 kinase (PI3K)/Akt signalling pathway is essential for maintaining the
integrity of fundamental cellular processes, cell growth, survival, death and metabolism, and …

[HTML][HTML] Molecular and genomic alterations in glioblastoma multiforme

I Crespo, AL Vital, M Gonzalez-Tablas… - The American journal of …, 2015 - Elsevier
In recent years, important advances have been achieved in the understanding of the
molecular biology of glioblastoma multiforme (GBM); thus, complex genetic alterations and …

Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

C Brito, A Azevedo, S Esteves, AR Marques, C Martins… - Bmc Cancer, 2019 - Springer
Background Significant advances in the molecular profiling of gliomas, led the 2016 World
Health Organization (WHO) Classification to include, for the first-time, molecular biomarkers …

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

T Kessler, D Schrimpf, L Doerner, L Hai, LD Kaulen… - Clinical Cancer …, 2023 - AACR
Purpose: The EORTC-26101 study was a randomized phase II and III clinical trial of
bevacizumab in combination with lomustine versus lomustine alone in progressive …

A practical review of prognostic correlations of molecular biomarkers in glioblastoma

M Karsy, JA Neil, J Guan, MA Mahan, H Colman… - Neurosurgical …, 2015 - thejns.org
Despite extensive efforts in research and therapeutics, achieving longer survival for patients
with glioblastoma (GBM) remains a formidable challenge. Furthermore, because of rapid …

PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis

F Han, R Hu, H Yang, J Liu, J Sui, X Xiang… - OncoTargets and …, 2016 - Taylor & Francis
Background We conducted this meta-analysis based on eligible trials to investigate the
relationship between phosphatase and tensin homolog (PTEN) genetic mutation and glioma …

Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies

J Balça-Silva, D Matias, A do Carmo… - Seminars in cancer …, 2019 - Elsevier
Glioblastoma (GB) is the more frequent and malignant brain tumour. In spite of all efforts, the
median overall survival of GB patients remains approximately 15 months under therapy. The …

[HTML][HTML] Clinical significance of PTEN deletion, mutation, and loss of PTEN expression in de novo diffuse large B-cell lymphoma

X Wang, X Cao, R Sun, C Tang, A Tzankov, J Zhang… - Neoplasia, 2018 - Elsevier
PTEN loss has been associated with poorer prognosis in many solid tumors. However, such
investigation in lymphomas is limited. In this study, PTEN cytoplasmic and nuclear …

miR-21 is linked to glioma angiogenesis: a co-localization study

SK Hermansen, BS Nielsen… - … of histochemistry & …, 2016 - journals.sagepub.com
MicroRNA-21 (miR-21) is the most consistently over-expressed microRNA (miRNA) in
malignant gliomas. We have previously reported that miR-21 is upregulated in glioma …